3999-05-1Relevant articles and documents
Synthesis and antibacterial activity in?vitro of 2-benzylthioimidazo[1,2-a]pyridine derivatives against pathogenic bacterial
Ablo, Evrard,Coulibali, Siomenan,Touré, Daouda,Coulibaly, Souleymane,Kablan, Ahmont Landry Claude,Konan Kouadio, Fernique,Sissouma, Drissa,Guessend Kouadio, Nathalie,Ané, Adjou
, p. 462 - 469 (2022/02/25)
To explore the antibacterial activity, a set of new 2-thiobenzyl-3-nitro-imidazo[1,2-a]pyridine derivatives were synthesized (9a–h) and characterized by NMR 1H, 13C and high-resolution mass (HRMS). These compounds were obtained by interaction between the 3-nitro-imidazo[1,2-a]pyridine isothiouronium salt (7) with benzyl chloride or bromide (8) in the presence of sodium hydroxide (NaOH). Eight (9a–h) of them were evaluated in?vitro on the positive gram bacterium (S. aureus ATCC 29213) and two others negative gram bacteria (P. aeruginosa ATCC 27853 and P. aeruginosa 933 C/21) by methods diffusion in solid medium and liquid macrodilution. Five among the eight compounds (9a, 9d, 9h, 9f and 9g) showed significant antibacterial activity on P. aeruginosa ATCC 27853 and P. aeruginosa 933 C/21with MIC between 7.81 and 250 μg/mL. All compounds were inactive on S. aureus. The compounds 9a and 9g were more potent on the two strains of P. aeruginosa ATCC 27853.
Structural Determinants for the Mode of Action of Imidazopyridine DS2 at δ-Containing γ-Aminobutyric Acid Type A Receptors
Rostrup, Frederik,Falk-Petersen, Christina B.,Harpsoe, Kasper,Buchleithner, Stine,Conforti, Irene,Jung, Sascha,Gloriam, David E.,Schirmeister, Tanja,Wellendorph, Petrine,Frolund, Bente
, p. 4730 - 4743 (2021/05/06)
Despite the therapeutic relevance of δ-containing γ-aminobutyric acid type A receptors (GABAARs) and the need for δ-selective compounds, the structural determinants for the mode and molecular site of action of δ-selective positive allosteric modulator imi
Synthesis and Physicochemical Properties of New Chalcones Containing a 2-Chloroimidazo[1,2-a]pyridine Fragment
Abashev, G. G.,Chukhlantseva, A. N.,Ermolov, D. A.,Lunegov, I. V.,Mokrushin, I. G.,Shklyaeva, E. V.
, p. 1940 - 1947 (2022/01/24)
Abstract: New chalcones containing a 2-chloroimidazo[1,2-a]pyridine fragment have been synthesized, and their optical properties have been studied. The Stokes shifts, forbidden band gap widths, molar absorption coefficients, and fluorescence quantum yields have been determined on the basis of their absorption and emission spectra. Introduction of an additional thiophene fragment into the chalcone molecules produced an increase of the Stokes shift, red shift of the emission maximum, and sharp increase of the quantum yield (up to 22%). The synthesized chalcones showed high thermal stability and good film-forming properties, and films obtained therefrom exhibited an ordered structure.
FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS
-
Page/Page column 91, (2020/12/30)
The present invention discloses a fused heterocyclic compound of formula (I), wherein, R1, Y, Q, A, G,m and E are as defined in the detailed description. The present invention further discloses methods for their preparation and use of the compounds of formula (I) as a pest control agent.
Pyrrolo-imidazo[1,2- A[pyridine Scaffolds through a Sequential Coupling of N-Tosylhydrazones with Imidazopyridines and Reductive Cadogan Annulation, Synthetic Scope, and Application
Zhang, Kena,El Bouakher, Abderrahman,Levaique, Helene,Bignon, Jerome,Retailleau, Pascal,Alami, Mouad,Hamze, Abdallah
, p. 13807 - 13823 (2019/10/16)
A new strategy for the construction of 3-phenyl-1H-pyrrolo-imidazo[1,2-a]pyridine backbone is described. The reaction starts from the coupling between N-tosylhydrazones and 2-chloro-3-nitroimidazo[1,2-a]pyridines leading to the formation of 3-nitro-2-(ary
TRPC5 INHIBITORS AND METHODS OF USING SAME
-
, (2019/04/10)
Provided herein are TRPC5 inhibitors and methods of using the same, e.g., to protect podocytes and/or treat kidney disease.
Synthesis and Structure of 2-(1Н-Indol-1-yl)-6-ferrocenyl-4-(2-chloroimidazo[1,2-a]pyridin-3-yl)pyrimidine
Antuf’eva,Akhmatzyanova,Dmitriev,Shklyaeva,Abashev
, p. 1103 - 1107 (2018/08/16)
A 2,4,6-trisubstituted pyrimidine including a 2-(1H-indol-1-yl) substituent was synthesized by the reaction of 1-ferrocenyl-3-(2-chloroimidazo[1,2-a]pyridin-3-yl)propanone with 2,5-dimethoxytetrahydrofuran. The structure of the synthesized compound was confirmed by IR and 1Н NMR spectroscopy, and X-ray diffraction analysis. It has been shown that the ferrocene-containing compounds synthesized in the present work all demonstrate intramolecular charge transfer which is evidenced by the observation of the corresponding absorption bands with λmaxabs > 480 nm. The oxidation potential of ferrocene (EoxFc) in all the compounds is higher than 700 mV.
Regiocontrolled functionalization of 2,3-dihalogenoimidazo[1,2-a]pyridines by Suzuki-Miyaura and Sonogashira cross-coupling reactions
Delaye,Pénichon,Allouchi,Enguehard-Gueiffier,Gueiffier
supporting information, p. 4199 - 4203 (2017/07/10)
An efficient method for regiocontrolled functionalization of 2,3-dihalogenoimidazo[1,2-a]pyridine was developed. This sequence allowed the selective introduction of aryl, heteroaryl, alkyl and alkynyl substituents at both 2- and 3-positions, by using Suzu
Insights into selenylation of imidazo[1,2-a]pyridine: synthesis, structural and antimicrobial evaluation
Kumar, Sanjeev,Sharma, Nidhi,Maurya, Indresh K.,Verma, Ajay,Kumar, Sangit,Bhasin,Sharma, Rohit K.
, p. 2919 - 2926 (2017/04/17)
An efficient methodology was developed to synthesize novel organoselenium derivatives of formyl-substituted imidazo[1,2-a]pyridine by nucleophilic aromatic substitution with aryl selenolate anions generated in situ through the reduction of different disel
Double (amino-sulfur generation of formic acid ) - 1,3-propane diester compound and its synthetic method, pharmaceutical composition and use thereof
-
, (2016/10/08)
The invention relates to a bis(aminodithioformate)-1,3-propane diester compound, and synthesis method thereof, a pharmaceutical composition containing the compound and a use, and especially relates to the use in preparing drugs for treating or preventing cancers. The compound is represented as the formula (I), wherein A is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic group, R1 and R2 are the same or different and are independently selected from hydrogen, alkyl, aryl alkyl or heteroaryl alkyl, or a substituted or unsubstituted heterocyclic ring formed together by the R1, the R2 and an N atom connected with the R1 and the R2.